| Literature DB >> 23613977 |
Andrzej F Frydrychowski1, Pawel J Winklewski, Arkadiusz Szarmach, Grzegorz Halena, Tomasz Bandurski.
Abstract
PURPOSE: The purpose of the study was to assess the responses of pial artery pulsation (cc-TQ) and subarachnoid width (sas-TQ) to acetazolamide challenge in patients with chronic carotid artery stenosis and relate these responses to changes in peak systolic velocity (PSV), cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT) and time to peak response (TTP).Entities:
Mesh:
Substances:
Year: 2013 PMID: 23613977 PMCID: PMC3629110 DOI: 10.1371/journal.pone.0061936
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Patients' characteristics.
| Patient No. | Age | Gender | Cerebrovascular History | Vascular Pathology | Concomitant Diseases | cc-TQ Ratio Ipsilateral/Contralateral |
| 1. | 70 | Male | Previous left CAS | LICA restenosis >90% | Coronary artery disease, previous myocardial infarction, CABG and PTCA, hypertension, renal impairment | Baseline: 0.5 Diamox: 0.5 |
| 2. | 69 | Male | Recent stroke of the right hemisphere with transient contralateral hemiplegia | RICA stenosis >95% | Hypertension | Baseline: 1.3 Diamox: 1.1 |
| 3. | 80 | Female | Previous RICA surgical CEA | RICA restenosis >90% | Hypertension | Baseline: 0.8 Diamox: 0.7 |
| 4. | 60 | Female | Recent stroke of the left hemisphere with transient bracho-facial hemiparesis | LICA occlusion in intraoperative angiography | Hypertension, diabetes mellitus, coronary artery disease | Baseline: 0.9 Diamox: 1.2 |
| 5. | 60 | Female | Previous stent implantation for 99% stenosis in LICA | RICA stenosis >90% | Hypertension, coronary artery disease, multiple myocardial infarctions in medical history | Baseline: 0.5 Diamox: 0.6 |
| 6. | 58 | Male | Previous RICA surgical CEA | RICA restenosis >90% | Hypertension, dyslipidaemia, previous myocardial infarction, CABG and PTCA | Baseline: 1.0 Diamox: 1.0 |
| 7. | 82 | Male | Previous left subclavian artery revascularization with stent implantation | LICA stenosis >90% | Hypertension, coronary artery disease, peripheral arterial disease, previous PTCA | Baseline: 1.0 Diamox: 1.1 |
| 8. | 70 | Male | Previous TIA | LICA stenosis >90% | Hypertension, diabetes mellitus, coronary artery disease, previous myocardial infarction, PTCA, and lower limb endovascular and open revascularization | Baseline: 1.3 Diamox: 1.1 |
| 9. | 70 | Female | Previous TIA | LICA occlusion in intraoperative angiography | Hypertension, coronary artery disease, previous myocardial infarction | Baseline:1.3 Diamox: 1.2 |
| 10. | 71 | Male | Previous LICA surgical CEA with subsequent carotid artery stenting | RICA stenosis >95% | Hypertension, peripheral arterial disease, coronary artery disease, previous myocardial infarction | Baseline:1.6 Diamox: 1.3 |
| 11. | 71 | Male | Previous RICA surgical CEA | LICA stenosis >95% | Hypertension, coronary artery disease, previous myocardial infarction, CABG and PTCA, previous peripheral vascular surgery | Baseline: 0.9 Diamox: 1.4 |
| 12. | 66 | Male | Ischaemic stroke of the left hemisphere with contralateral hemiparesis and aphasia. Previous surgical LICA CEA | LICA restenosis >95% | Hypertension | Baseline:1.6 Diamox: 1.3 |
| 13. | 81 | Male | Previous RICA surgical CEA | LICA stenosis >90% | Hypertension, dyslipidaemia, coronary artery disease. Previous PTCA | Baseline: 0.7 Diamox: 0.7 |
| 14. | 68 | Male | Ischaemic stroke of the right hemisphere | RICA stenosis >90% | Hypertension | Baseline:0.8 Diamox: 1.0 |
| 15. | 71 | Female | Three strokes in the past with aphasia and transient right-sided plegia | LICA stenosis >90% | Hypertension, diabetes mellitus, atrial fibrillation | Baseline: 1.1 Diamox: 1.2 |
cc-TQ–pial artery pulsation (cardiac component of the transillumination quotient); CABG–coronary artery bypass grafting; CAS–carotid artery stenting; CEA–carotid endarterectectomy; LICA–left internal carotid artery; PTCA–percutaneous transluminal coronary angioplasty; RICA–right internal carotid artery; TIA–transient ischaemic attack.
Mean (± SE) values of cc-TQ, sas-TQ, MTT, CBV, CBF, TTP and PSV before and after acetazolamide challenge in hemisphere ipsilateral and contralateral to stenosis. The whole patient population (n = 15).
| Variable | Baseline | Acetazolamide challenge | ||
| Ipsilateral | Contralateral | Ipsilateral | Contralateral | |
|
| 69.7±6.8 | 73.3±8.0 | 84.0±9.3*** | 94.6±13.6*** |
|
| 10612.9±982.4 | 10241.3±1311.3 | 9865.9±998.8 | 9346.1±1298.7** |
|
| 6.7±0.2 | 6.41±0.1 | 6.42±0.3NS | 5.95±0.1** |
|
| 2.07±0.1 | 2.0±0.1 | 2.42±0.2*** | 2.29±0.1*** |
|
| 22.7±0.9 | 22.9±0.8 | 27.5±1.5*** | 27.8±1.2*** |
|
| 26.4±1.0 | 26.0±1.1 | 24.7±1.0*** | 24.4±1.0*** |
|
| 126.2±37.6 | 79.2±8.0 | 167.3±33.9** | ±8.0*** |
|
| 74.3±3.5 | 74.1±3.5NS | ||
p<0.05, **p<0.01, ***p<0.001, NSnot statistically significant, acetazolamide challenge versus baseline.
cc-TQ–pial artery pulsation (cardiac component of the transillumination quotient); sas-TQ–the subarachnoid width (subarachnoid component of the transillumination quotient); MTT–mean transit time; CBV–cerebral blood volume; TTP–time to peak; PSV–peak systolic velocity; HR–Heart Rate; SE–standard error; ml–millilitres; g–gram; min.–minutes; s–seconds; cm–centimetres.
Figure 1Representative cc-TQ recording before and after acetazolamide challenge.
Vertical blue line indicates time of acetazolamide administration. cc-TQ–pial artery pulsation (cardiac component of the transillumination quotient).
Mean (± SE) values of cc-TQ, sas-TQ, MTT, CBV, CBF, TTP and PSV before and after acetazolamide challenge in hemisphere ipsilateral and contralateral to stenosis. Patient population with cc-TQ ipsilateral/contralateral ratio ≥1 (n = 10).
| Variable | Baseline | Acetazolamide challenge | ||
| Ipsilateral | Contralateral | Ipsilateral | Contralateral | |
|
| 71.4±6.7 | 58.6±7.3 | 90.4±8.8** | 74.3±7.0## *** |
|
| 10595.3±1083.9 | 10407.1±1433.4 | 9514.6±979.2*** | 9220.1±1358.4** |
|
| 6.9±0.3 | 6.5±0.2 | 6.7±0.4NS | 6.0±0.2 |
|
| 2.1±0.2 | 2.0±0.1 | 2.4±0.2 | 2.2±0.1 |
|
| 22.9±1.3 | 22.7±0.8 | 26.4±2.1 | 26.7±1.7 |
|
| 26.4±1.3 | 25.6±1.5 | 24.5±1.2*** | 23.9±1.2*** |
|
| 131.8±56.2 | 80.0±7.6 | ±50.2 | 121.1±7.1 |
p<0.05 baseline: ipsilateral vs contralateral;
p<0.05, ##p<0.01 acetazolamide challenge: ipsilateral versus contralateral;
p<0.05, **p<0.01, ***p<0.001, NSnot statistically significant, acetazolamide challenge versus baseline.
cc-TQ–pial artery pulsation (cardiac component of the transillumination quotient); sas-TQ–the subarachnoid width (subarachnoid component of the transillumination quotient); MTT–mean transit time; CBV–cerebral blood volume; TTP–time to peak; PSV–peak systolic velocity; SE–standard error; ml–millilitres; g–gram; min.–minutes; s–seconds; cm–centimetres.
Mean (± SE) values of cc-TQ, sas-TQ, MTT, CBV, CBF, TTP and PSV before and after acetazolamide challenge in hemisphere ipsilateral and contralateral to stenosis. Patient population with cc-TQ ipsilateral/contralateral ratio <1 (n = 5).
| Variable | Baseline | Acetazolamide challenge | ||
| Ipsilateral | Contralateral | Ipsilateral | Contralateral | |
|
| 66.4±12.0 | 102.8±7.3 | 91.2±19.6 | 135.2±33.2NS |
|
| 10648.0±2201.3 | 9909.6±2960.9 | 10568.6±2444.5NS | 9598.2±3062.9NS |
|
| 6.22±0.2 | 6.3±0.2 | 5.9±0.3NS | 5.8±0.3NS |
|
| 1.9±0.1 | 2.0±0.2 | 2.4±0.1** | 2.4±0.1 |
|
| 22.4±1.3 | 23.5±1.7 | 29.8±1.2** | 29.8±0.8** |
|
| 26.5±1.8 | 26.7±1.8 | 25.0±1.7NS | 25.5±1.6NS |
|
| 115.0±26.3 | ±21.7 | 149.5±26.4 | 127.5±22.9 |
p<0.05 baseline: ipsilateral vs contralateral;
p<0.05, **p<0.01, NSnot statistically significant, acetazolamide challenge versus baseline.
cc-TQ–pial artery pulsation (cardiac component of the transillumination quotient); sas-TQ–the subarachnoid width (subarachnoid component of the transillumination quotient); MTT–mean transit time; CBV–cerebral blood volume; TTP–time to peak; PSV–peak systolic velocity; SE–standard error; ml–millilitres; g–gram; min.–minutes; s–seconds; cm–centimetres.
Comparison of mean (± SE) percentage changes after acetazolamide challenge versus baseline in patients with ipsilateral/contralateral cc-TQ ratio ≥1 and <1.
| Variable | cc-TQ ≥1 | cc-TQ <1 | ||
| Ipsilateral | Contralateral | Ipsilateral | Contralateral | |
|
| +26.6%±8.6% | +26.8%±8.2% | +37.3%±9.3% | +31.5%±6.0NS |
|
| −10.2%±1.5% | −11.4%±2.7% | −0.7%±1.5% | −3.1%±5.7%NS |
|
| −2.9%±3.8% | −7.7%±2.1% | −5.1%±2.5%NS | −7.9%±3.5%NS |
|
| +14.3%±5.1% | +10.0%±3.7% | +26.3%±6.6% | +20.0%±7.3% |
|
| +15.3%±4.4% | +17.6%±5.6% | +33.0%±8.1% | +26.8%±7.0% |
|
| −7.2%±1.1% | −6.6%±0.8% | −5.7%±3.8%NS | −4.5%±2.4%NS |
|
| +33.8%±15.4% | +51.4±8.3% | +30.0%±11.8%NS | +64.5%±20.0%NS |
p<0.05, NSnot statistically significant, group of patients with ipsilateral/contralateral cc-TQ ratio ≥1 versus group of patients with cc-TQ <1.
cc-TQ–pial artery pulsation (cardiac component of the transillumination quotient); sas-TQ–the subarachnoid width (subarachnoid component of the transillumination quotient); MTT–mean transit time; CBV–cerebral blood volume; TTP–time to peak; PSV–peak systolic velocity; SE–standard error; ml–millilitres; g–gram; min.–minutes; s–seconds; cm–centimetres.